Depressions with eating disorders: clinical manifestations and therapy

The clinical and etiological diversity of depressive, anxiety, dysmorphic and psychotic disorders of the generative cycle in women necessitates an integrated approach to evaluation and treatment methods.During an individual approach to treatment administration, it is necessary to take into account the risk factors (heredity, comorbid disorders, gender, age, etc.) of adverse events, the spectrum of endocrine side effects characteristic of each drug, the balance of drug efficacy and safety.The effectiveness of hormone replacement therapy, including in combination with “fortifying” drugs, vitamins, dietary supplements, physiotherapy, in mental disorders has not been proven.Psychopharmacotherapy should include modern antidepressants, anxiolytics, antipsychotics with an emphasis on good tolerance, a minimum of adverse events, compatibility with hormonal therapy, and ease of dosing.Psychotherapy, psychological support and psycho-correction can reduce the severity of anxiety and depressive symptoms and significantly increase the treatment effectiveness.

Treatment of mental disorders of generative cycle in women

Medvedev

2022

Impact of work and study during pandemic on the mental state of medical professionals

Medvedev¹,

Dogotar

Lyzlova

2022

The COVID-19 pandemic is causing a heavy increase in the incidence of development/exacerbation of mental disorders in healthcare workers. The relevance and importance of early detection of predisposition to the development of mental disorders is increasing not only among practicing physicians, but also among clinical residents and students of medical universities.Objective: to assess the emotional state in different groups of medical workers and medical students.Patients and methods. The study involved 110 doctors of both sexes, including 64 (68.2%) women and 46 (41.8%) men aged 26–40 years who took upgrade training courses at the RUDN University departments; 108 residents of the second year of study aged 24–26, of which 67 (62.1%) women and 41 (37.9%) men, and 43 students of the 1st year of RUDN University aged 17–19, of which 29 (67.4%) women and 14 (32.6%) men. The study was conducted in February–May 2021. The research methods included questionnaires and psychometric assessment of the condition of the subjects and statistical data processing.Results and discussion. We documented a high frequency of signs of psychopathological disorders such as anxiety (44.5%), depression (23.6%), asthenia (86.4%) and eating behavior disorders (up to 68.2%) among practicing physicians of various specialties and students (residents and students) during pandemic.Conclusion. The stressful impact of the pandemic on the work and training of medical professionals leads to a deterioration in their mental health.

Agomelatine: pharmacological profile, possible application, advantages

Medvedev,

Kotova,

Palin

et al. 2024

Agomelatine is an antidepressant with a unique pharmacological action that is both a melatonin agonist and a selective serotonin antagonist. The drug's unique pharmacological profile includes the properties of a dual 5-HT2С receptor antagonist as well as the properties of a melatonin MT1 and MT2 receptor agonist. Through its effect on melatonin receptors, agomelatine resynchronizes disturbed circadian rhythms and has a positive effect on sleep architecture. In addition, agomelatine shows a novel and fundamentally different mechanism of anxiolytic action compared to other classes of drugs used to treat anxiety. The article presents studies of agomelatine that demonstrate good treatment results in terms of response rates and remission in major depressive disorder of varying severity and generalized anxiety disorder. Agomelatine in a daily dose of 25–50 mg not only reduces the degree of anhedonia, apathy, anxiety, reduces somatic symptoms of depressive and anxiety disorders, but is also well tolerated, normalizes sexual dysfunctions in patients in psychiatric and general medical networks, it is used in cardiovascular, neurological diseases, and post-COVID-19.